Moderna extends gains

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
The agency had for years said it could not conclude whether COVID-19 was the result of a lab incident or it originated in ...
Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...